Latest Roche news and updates from Switzerland. AI-curated articles covering Roche topics.
A look at major developments in Switzerland's corporate world. The SNB confirms UBS's crisis resilience as the bank plans a US expansion, Roche announces a successful trial for a new lung cancer drug, and retailer Migros opens its first 24-hour automated supermarket.
Swiss pharmaceutical giant Roche has announced an agreement to acquire PathAI, a US-based artificial intelligence specialist, for $750 million. The acquisition aims to bolster Roche's position in AI-driven diagnostics and accelerate the development of personalized medicine.
Swiss pharmaceutical giant Roche is significantly expanding its footprint in digital pathology with the acquisition of US-based AI firm PathAI. The deal aims to merge Roche's diagnostic expertise with AI-powered systems to accelerate drug development and advance personalized medicine.
Swiss pharmaceutical firm Roche announced first-quarter sales of CHF 14.7 billion, a 5% decrease in its reporting currency due to the strong franc. However, the company highlighted a 6% increase at constant exchange rates, driven by its Pharmaceuticals Division, which met analyst targets.
US policies aimed at lowering prescription drug prices are forcing Swiss pharmaceutical companies like Novartis and Roche to reassess their European strategies. Companies are signing 'Most Favoured Nation' deals to align prices, which could reshape investment and innovation in Switzerland's vital pharma sector.
The US Food and Drug Administration (FDA) has approved a new oral combination therapy for chronic lymphocytic leukaemia developed by Genentech, a US subsidiary of Swiss pharmaceutical giant Roche, offering a new time-limited, non-chemotherapy option for patients.
Basel-based pharmaceutical firm Roche announced a successful 2025, with sales increasing by 2% to CHF61.5 billion. The company reported a net profit of CHF13.8 billion, a significant rise from the previous year.
Swiss pharmaceutical giant Roche has announced that its experimental obesity drug, CT-388, led to an average body weight loss of over 20% in a Phase II clinical trial, marking a significant step into the highly competitive weight-loss drug market.
Swiss pharmaceutical giant Roche has reported highly positive results from a trial of its experimental obesity drug, CT-388, showing significant weight loss and positioning the company in the competitive weight-loss drug market.
Swiss pharmaceutical giant Roche receives European Commission approval for Columvi, marking a significant breakthrough in lymphoma treatment options.
From trusted Swiss news outlets